MX2023003654A - Vector de combinación de neurod1. - Google Patents

Vector de combinación de neurod1.

Info

Publication number
MX2023003654A
MX2023003654A MX2023003654A MX2023003654A MX2023003654A MX 2023003654 A MX2023003654 A MX 2023003654A MX 2023003654 A MX2023003654 A MX 2023003654A MX 2023003654 A MX2023003654 A MX 2023003654A MX 2023003654 A MX2023003654 A MX 2023003654A
Authority
MX
Mexico
Prior art keywords
neurod1
combination vector
vector
lhx3
ascl1
Prior art date
Application number
MX2023003654A
Other languages
English (en)
Inventor
Jie Xu
Original Assignee
Neuexcell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuexcell Therapeutics Inc filed Critical Neuexcell Therapeutics Inc
Publication of MX2023003654A publication Critical patent/MX2023003654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente divulgación se refiere a vectores AAV, composiciones y métodos relacionados con la conversión de neurogliocitos en neuronas mediante el uso de una secuencia codificante de NeuroD1 y secuencias codificantes de Ascl, ISL1 o LHX3 en un vector AAV.
MX2023003654A 2020-09-29 2021-09-28 Vector de combinación de neurod1. MX2023003654A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084971P 2020-09-29 2020-09-29
US202163247439P 2021-09-23 2021-09-23
PCT/US2021/052358 WO2022072325A1 (en) 2020-09-29 2021-09-28 Neurod1 combination vector

Publications (1)

Publication Number Publication Date
MX2023003654A true MX2023003654A (es) 2023-06-22

Family

ID=80823426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003654A MX2023003654A (es) 2020-09-29 2021-09-28 Vector de combinación de neurod1.

Country Status (7)

Country Link
US (1) US20220098255A1 (es)
EP (1) EP4221761A1 (es)
JP (1) JP2023543362A (es)
AU (1) AU2021353867A1 (es)
CA (1) CA3197178A1 (es)
MX (1) MX2023003654A (es)
WO (1) WO2022072325A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552003A (ja) * 2019-10-17 2022-12-14 ザ・ペン・ステイト・リサーチ・ファウンデイション 脊髄損傷およびａｌｓの治療のための機能的ニューロンの再生

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2009114673A2 (en) * 2008-03-14 2009-09-17 The General Hospital Corporation Methods for production of atrial progenitors and their differentiation into smooth muscle cells and cardiomyocytes
BR112013003031A2 (pt) * 2010-08-19 2016-06-14 Hoffmann La Roche método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs
WO2013025963A2 (en) * 2011-08-17 2013-02-21 President And Fellows Of Harvard College Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
WO2013071440A1 (en) * 2011-11-18 2013-05-23 UNIVERSITé LAVAL Methods and products for increasing frataxin levels and uses thereof
DE18200782T1 (de) * 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9943574B2 (en) * 2012-06-27 2018-04-17 Arthrogen B.V. Combination for treating an inflammatory disorder
CN113559281A (zh) * 2012-07-19 2021-10-29 宾夕法尼亚州研究基金会 再生用于在神经系统中治疗疾病和损伤的功能性神经元
WO2014142984A1 (en) * 2013-03-15 2014-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Coincidence reporter gene system
SG11201510286QA (en) * 2013-06-17 2016-01-28 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
KR101712247B1 (ko) * 2014-09-29 2017-03-06 단국대학교 산학협력단 암 특이적 트랜스-스플라이싱 라이보자임 및 이의 용도
WO2016172155A1 (en) * 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
EP3416663B1 (en) * 2016-02-18 2021-04-14 The Penn State Research Foundation Generating gabaergic neurons in brains
CA3044593A1 (en) * 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US10724052B2 (en) * 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
CA3115534A1 (en) * 2018-10-22 2020-04-30 Inscripta, Inc. Engineered nucleic acid-guided nucleases
AR117145A1 (es) * 2018-11-21 2021-07-14 Stridebio Inc Vectores virales recombinantes y ácidos nucleicos para producirlos
EP3894550A4 (en) * 2018-12-14 2023-01-04 Pioneer Hi-Bred International, Inc. NEW CRISPR-CAS SYSTEMS FOR GENOME EDITING

Also Published As

Publication number Publication date
JP2023543362A (ja) 2023-10-13
AU2021353867A9 (en) 2023-06-29
AU2021353867A1 (en) 2023-05-11
CA3197178A1 (en) 2022-04-07
WO2022072325A1 (en) 2022-04-07
EP4221761A1 (en) 2023-08-09
US20220098255A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
MX2023003654A (es) Vector de combinación de neurod1.
MX2022006365A (es) Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos.
MY189001A (en) Adaptive switching of color spaces, color sampling rates and/or bit depths
WO2013025963A3 (en) Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
MX2016012636A (es) Ajuste de cuantificacion/escalamiento y cuantificacion/escalamient o inverso cuando se cambian espacios de color.
MX2019002228A (es) Ajuste de tasa en memeoria intermedia circular para códigos polares.
MX2021006925A (es) Composiciones y metodos heterologos de vacunacion con refuerzo inductor.
MX2020012061A (es) Composiciones que comprenden cepas bacterianas.
MX347453B (es) Canalrodopsina 2 mutante.
MY164987A (en) Audio/speech encoding apparatus, audio/speech decoding apparatus, and audio/speech encoding and audio/speech decoding methods
EP3754484A3 (en) Generating encoding software and decoding means
MX2021000638A (es) Métodos y composiciones de construcciones y vectores de acidemia metilmalónica.
MY196192A (en) Methods and Devices for Encoding And Decoding Binary Data
MX2021014949A (es) Recubrimientos resistentes a la incrustación biológica y métodos para elaborar y usar los mismos.
GB2456728A (en) Run-length encoding of binary sequences followed by two independent compressions
WO2010108043A3 (en) Finite rate of innovation (fri) techniques for low power body area network (lp-ban) communications
MX363057B (es) Cepa de e. coli f18 no patogenica y uso de la misma.
MX2021012676A (es) Composiciones probioticas y usos de las mismas.
MX2023003657A (es) Vector neurod1 y dlx2.
MX2024004331A (es) Difosfato de uridina glucosiltransferasa novedoso y su uso.
EA202191460A1 (ru) Газонаполненное упругое тело и его применение
MX2023003655A (es) Vector neurod1.
EP2048787A4 (en) METHOD AND DEVICE FOR QUANTIFYING VECTORS
MX2023003656A (es) Vector dlx2.
AU2018261974A1 (en) Method and Apparatus for Sequence Determination, Device and Storage Medium